Eli Lilly has thrown its weight behind a cause beyond the traditional remit of pharma companies. | Eli Lilly has thrown its ...

Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...

Lilly announces positive results from phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease: Indianapolis Tuesday, October 15, 2024, 18:00 Hrs [IST] Eli Lilly a ...

On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of ...

J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona ...

Hims & Hers Health (NYSE:HIMS) is up ~10% in Monday morning trading following a recent lawsuit challenging the U.S. FDA's ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Results from the national "Urgent Conversations" survey, announced today by Eli Lilly and Company (NYSE: LLY), found that ...

Eli Lilly announced data demonstrating more patients with moderately to severely active Crohn’s disease treated with ...

Data show more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab INDIANAPOLIS, Oct. /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data ...